Loading
Imagenomix
Imagenomix, a spinout of NYU Langone, makes software that looks at a standard biopsy slide and predicts which cancer-driving mutations the tumour has, in minutes and without using up tissue, starting with lung cancer.
Overview
Imagenomix grew out of research at NYU Langone Health, where its founders, the pathologists Aristotelis Tsirigos, Matija Snuderl and Daniel Orringer, showed that AI could infer a tumour's driver mutations from H&E-stained slides. Its IGX Predict platform installs alongside digital pathology scanners and, according to NYU's launch announcement, returns a report to the doctor in about three minutes. The lung product, Pulmogene, is listed as commercial; a breast product (BLISS) is in development, and brain (NeuroInsight) and melanoma (DermPredict) products are on the roadmap. Travis Wold is chief executive.
Notes
- Founding year not stated by the company; its timeline places commercial launch of IGX Predict in 2023 and NYU announced the startup's launch in about 2024. A USD 3.2 million seed round in May 2026, reported by GenomeWeb as led by Modi Ventures, could not be read in a primary source, so no funding row is recorded. Regulatory status of the products is not stated on the company website.
Connected
6Similar pages
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
imagenomix.ai · 1
A source that has moved or gone is reported by the weekly link check. /audit/